Gufic BioSciences share price today

Gufic BioSciences Ltd's share price was ₹428.90 at the close on 4 November 2026. It has been rising for 18 weeks. That is 13.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹279 and ₹445, and at that close it sat 90% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Gufic BioSciences Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 31 weeks in a row.

Over the last 11 years the share price moved +865% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

1. Revenue up on a year earlier for 7 quarters in a row

   In the June 2026 quarter revenue was ₹261 crore, +16.5% on a year earlier.

   Why: Revenue rose because the international business started earning fees and licensing income and got its first overseas contract manufacturing orders. Making GLP-1 products for Hetero also began.

   Next results: check whether the Indore plant gets used enough to reach the stated range by the end of the year.

   From the earnings call on 17 Aug 2026.

3. Highest quarterly revenue in 12 quarters

   Revenue of ₹261 crore in the June 2026 quarter is the highest of the last 12 quarters.

   Why: Revenue reached a 12-quarter high because the international business started earning fees and licensing income and got its first overseas contract manufacturing orders. Making GLP-1 products for Hetero also began.

   From the earnings call on 17 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Gufic BioSciences reported revenue of ₹261 crore, up 16.5% from ₹224 crore a year earlier, and a profit of ₹22.0 crore, up 69.2% from ₹13.0 crore.

Gufic BioSciences results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Gufic BioSciences' management discussed these results on a call held on 17 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Gufic BioSciences closed at ₹428.90 on 4 November 2026, up 28.4% from ₹334.05 a year earlier (7 November 2025) and up 128.4% over five years. Its highest weekly close since March 2016 was ₹485.45 on 8 November 2024.

Gufic BioSciences share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Gufic BioSciences closed at ₹428.90, up 4.1% on the week and up 2.6% on the month. 28 Aug 2026: ex-date for a dividend of ₹0.10 a share.

Earlier

• 17 Aug 2026: Gufic BioSciences held its results call for April to June 2026. Management guided: Company growth of 15-20% on a year earlier for FY27; 15% described as the bare minimum.
• Results for April to June 2026: Revenue up 16.5% and profit up 69.2% on a year earlier.

Gufic BioSciences paid ₹0.10 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.02% at the ₹428.90 close on 4 November 2026. The last was a dividend of ₹0.10 a share, ex-date 28 August 2026.

Gufic BioSciences dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Gufic BioSciences Ltd paid out 2% of its profit as dividends in FY26, and it paid a dividend in each of its last 3 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 17 August 2026, Gufic BioSciences' management guided: Company growth of 15-20% on a year earlier for FY27; 15% described as the bare minimum.

“Our revenues would be purely as a CMO. Again, I am reiterating that we are not going to do any front-end, neither in India nor abroad.”Pranav Choksi, on the call for April to June 2026

What management guided

• Indore utilization planned at 40-45% by FY27 year-end; EU certification feedback expected in 1-2 months, new depot/microsphere and lipid-antifungal lines planned during FY27, with leverage by mid-FY27-28.
• GLP-1 CMO activity expected to pick up in Q2 and gain momentum in Q3; end-year objective roughly 30% domestic and 70% international.
• Current-infrastructure revenue potential of ₹1,600-1,800 crore without capital spending, subject to current product mix and legacy realizations.
• Indore product mix over the next three years planned at 20% liquids, 50-60% lyophilization and 20-30% complex injectables.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 17 August 2026.

When Gufic BioSciences reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Indore utilization to reach the stated year-end range; check depot, microsphere and lipid-antifungal readiness plus export mix.

Gufic BioSciences is on 2 of our India lists: Momentum stocks and Pharma stocks.

Gufic BioSciences Ltd earned ₹22.0 Cr of net profit in the Jun 2026 quarter, +69.2% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹64.0 Cr. Over 2 years profit has grown −13.7% a year on average. That is 8.4% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹13.0 Cr.

For the full year, FY26 profit was ₹64.0 Cr (−8.6% on the year before).

Why profit moved: revenue changed +16.5% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +46.2% and revenue +16.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Gufic BioSciences Ltd reported ₹261 Cr of revenue in the Jun 2026 quarter, +16.5% on the same quarter a year earlier. That is the 7th quarter in a row with growth on the year before. Over 2 years it has grown 8.2% a year on average. The last full year, FY26, came in at ₹944 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹981 Cr.

FY26 revenue was ₹944 Cr, +15.1% on the year before.

Recent pace: the last four quarters grew +16.7% on average, against 8.2% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +16.6%, against +9.7% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +17.7%, against −7.9% a year (accelerating).

Gufic BioSciences Ltd's operating margin was 18.0% in the Jun 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Across 3 years it has been between 16.0% and 19.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +3.0 percentage points on the year while gross margin changed +1.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 73% of Gufic BioSciences Ltd's reported profit came in as cash from its operations, so most of the profit is real cash. In FY26 it brought in ₹45.0 Cr of operating cash against ₹64.0 Cr of profit. After ₹16.0 Cr of spending on assets, ₹29.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 73% of profit came in as cash: the cash cycle got 43 days longer between FY24 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 43 days longer. The next section looks at where the cash is stuck.

Gufic BioSciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 224 days in FY26, up from 181 days in FY24. It spent ₹99.0 Cr on assets over the last 2 years. Customers take 115 days to pay, and stock sits for 281 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹944 Cr, each day of that cycle ties up about ₹2.6 Cr, so roughly ₹579 Cr is tied up in the business at any time.

FY26: customers took 115 days to pay and stock sat for 281 days, about 9.2 months of sales sitting as stock, for a full cycle of 224 days, longer than FY24's 181.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 281 days. Customers pay about 115 days after that. Suppliers are paid at 172 days. Together that makes the 224-day cycle.

Spending on assets: ₹99.0 Cr over the last 2 years, against ₹52.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹22.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Gufic BioSciences Ltd's P/E is 58.5×, near the high end of its own history: higher than 77% of past readings. Its usual P/E (the middle reading) is 55.3×, over 2.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved −7.9% while the price moved +28.4%. The price did better than earnings, which pushed the multiple up within its own range.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Gufic BioSciences Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE rising at 16.9%; each line tells part of the story. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.